Literature DB >> 2161625

Effect of inhaled preservatives on asthmatic subjects. I. Sodium metabisulfite.

W Wright1, Y G Zhang, C M Salome, A J Woolcock.   

Abstract

Sodium metabisulfite (MBS) is used as a preservative in food and wine and frequently triggers attacks of asthma. To determine the characteristics of responses to inhaled MBS, 30 asthmatic subjects and 16 nonasthmatic subjects inhaled MBS, in concentrations of 6.2, 12.5, 50, and 100 mg/ml, from a DeVilbiss No. 40 nebulizer (DeVilbiss Co., Somerset, PA) in doses ranging from 0.1 to 12.8 mumol. Response was measured as the dose that caused a 20% fall in FEV1 (PD20FEV1). All the asthmatic subjects responded; one of the atopic, nonasthmatic subjects responded and none of the nonatopic, nonasthmatic subjects responded. The response occurred within 1 min, and most subjects recovered to within 10% of baseline after 30 to 40 min. Dose-response curves to MBS were steep and were reproducible, within a 7-day period, to within one doubling dose, with mean PD20FEV1 values of 2.17 and 2.11 mumol in 11 subjects. There was no correlation between PD20FEV1 values to MBS and histamine, and inhalation of MBS did not enhance responses to subsequent challenge with histamine (mean PD20FEV1 to histamine was 0.65 mumol and to histamine 1 h after MBS was 0.74 mumol). Challenge with MBS (mean PD20FEV1 4.07 mumol) did not cause refractoriness to a second challenge 1 h later (mean PD20FEV1 5.39 mumol). Of 20 subjects tested, prior inhalation of 8 mg nedocromil sodium blocked the response to MBS in 15 subjects and reduced it in two others. Cromolyn sodium (4 mg) blocked the response to MBS in three subjects but did not alter the mean PD20FEV1 in the remaining 17 subjects.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2161625     DOI: 10.1164/ajrccm/141.6.1400

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  13 in total

1.  Role of sulfite additives in wine induced asthma: single dose and cumulative dose studies.

Authors:  H Vally; P J Thompson
Journal:  Thorax       Date:  2001-10       Impact factor: 9.139

2.  Occupational asthma caused by dry metabisulphite.

Authors:  J L Malo; A Cartier; A Desjardins
Journal:  Thorax       Date:  1995-05       Impact factor: 9.139

Review 3.  Nedocromil sodium. An updated review of its pharmacological properties and therapeutic efficacy in asthma.

Authors:  R N Brogden; E M Sorkin
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

4.  Inhibition of sodium metabisulphite induced bronchoconstriction by frusemide in asthma: role of cyclooxygenase products.

Authors:  B J O'Connor; P J Barnes; K F Chung
Journal:  Thorax       Date:  1994-04       Impact factor: 9.139

5.  Comparison of sulphur dioxide and metabisulphite airway reactivity in subjects with asthma.

Authors:  P I Field; M McClean; R Simmul; N Berend
Journal:  Thorax       Date:  1994-03       Impact factor: 9.139

6.  Inhibition of inhaled metabisulphite-induced bronchoconstriction by inhaled frusemide and ipratropium bromide.

Authors:  G J Bellingan; C M Dixon; P W Ind
Journal:  Br J Clin Pharmacol       Date:  1992-07       Impact factor: 4.335

7.  Effects of sodium metabisulphite on guinea pig contractile airway smooth muscle responses in vitro.

Authors:  J Sun; T Sakamoto; K F Chung
Journal:  Thorax       Date:  1995-08       Impact factor: 9.139

8.  Effect of inhaled prostaglandin E2 on bronchial reactivity to sodium metabisulphite and methacholine in patients with asthma.

Authors:  I D Pavord; A Wisniewski; R Mathur; I Wahedna; A J Knox; A E Tattersfield
Journal:  Thorax       Date:  1991-09       Impact factor: 9.139

Review 9.  Topical pharmacotherapy for allergic rhinitis: nedocromil.

Authors:  R L Mabry
Journal:  Am J Otolaryngol       Date:  1993 Nov-Dec       Impact factor: 1.808

10.  Comparison of three inhaled non-steroidal anti-inflammatory drugs on the airway response to sodium metabisulphite and adenosine 5'-monophosphate challenge in asthma.

Authors:  M Wang; A Wisniewski; I Pavord; A Knox; A Tattersfield
Journal:  Thorax       Date:  1996-08       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.